UBS/CALL/ELI LILLY & CO/750.001/0.01/20.09.24

UBS/CALL/ELI LILLY & CO/750.001/0.01/20.09.24 Share Price

LLYFOU

CH1309048986

Market Closed - Swiss Exchange 16:20:00 23/05/2024 BST
0.93 ^CHF	+8.14%

Current month	+20.78%
1 month	+52.46%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart UBS/CALL/ELI LILLY & CO/750.001/0.01/20.09.24

Latest news about ELI LILLY AND COMPANY

Jefferies Adjusts Price Target on Eli Lilly to $925 From $915	02:59pm	MT
Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln	05:58am	RE
Radar Therapeutics announced that it has received $13.4 million in funding from NFX Capital Management, LLC, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors	22/05/2024	CI
Swiss Equities Tumble as UK Inflation Data Dampens June Rate Cut Hopes	05-22	MT

More news

Quotes 5-day view

Date	Price	Change
23/05/24	0.93	+8.14%
22/05/24	0.86	-2.27%
21/05/24	0.88	+29.41%
17/05/24	0.68	-2.86%
16/05/24	0.7	-2.78%

Delayed Quote Swiss Exchange

Last update May 23, 2024 at 04:20 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	UBS
	LLYFOU
ISIN	CH1309048986
Date issued	11/12/2023
Strike	750 $
Maturity	20/09/2024 (120 Days)
Parity	100 : 1
Emission price	0.21 CHF
Emission volume	N/A
Settlement	règlement en espèces
Currency	CHF

Technical Indicators

Highest since issue	0.99 CHF
Lowest since issue	0.17 CHF
Delta	0.76x
Omega	6.046
Premium	4.13x
Gearing	8x
Moneyness	1.091
Difference Strike	-58.45 $
Difference Strike %	-7.79%
Spread	0.01 CHF
Spread %	1.06%
Theoretical value	0.9350
Implied Volatility	29.60 %
Total Loss Probability	29.93 %
Intrinsic value	0.6261
Present value	0.3089
Break even	852.28 CHF
Theta	-0.02x
Vega	0.01x
Rho	0.02x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Eli Lilly and Company

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

802.9 USD

Average target price

850.8 USD

Spread / Average Target

+5.96%

Consensus